Physician profile
Lawrence Levine
NPI 1144331893
$1,996.47
in general payments reported to CMS, 2019-2025
27 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $92.38 · 2021: $159 · 2022: $142 · 2023: $346 · 2024: $363 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.60 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $315.94 | 2022-2025 | Miebo, Ic-8 Apthera Iol, Envista Mx60 Iol |
| Alcon Vision LLC | $309.75 | 2020-2025 | Tryptyr, Clareon, Unity |
| Johnson & Johnson Vision Care, INC. | $126.09 | 2020-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $116.56 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $104.49 | 2024-2025 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $100.00 | 2023 | |
| Abbvie INC. | $92.03 | 2022-2024 | |
| Oyster Point Pharma, INC. | $87.38 | 2023-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $74.71 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $70.48 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.09 | 2019 | |
| Allergan, INC. | $57.80 | 2019-2022 | |
| Dompe US, INC. | $52.25 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $51.29 | 2019-2022 | |
| Ocular Therapeutix, INC. | $50.25 | 2024 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.39 | 2025 | Izervay |
| Amgen INC. | $48.06 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $34.27 | 2022-2025 | Acthar |
| Sight Sciences, INC. | $32.63 | 2019 | |
| Horizon Therapeutics Plc | $26.72 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $23.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.85 | 2025 | Eylea Hd, Eylea |
| Omeros Corporation | $19.67 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.75 | 2024 | Syfovre |
| Harrow Eye, LLC | $17.34 | 2024 | Vevye |
| Eyepoint US, INC. | $15.93 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.